Phase 3 N=971 Long-term Study of Lemborexant in Insomnia Disorder (SUNRISE 2)
Insomnia Disorder
Primary: Change From Baseline in Subjective Sleep Onset Latency (sSOL) at Month 6 — 64.03; 62.19; 64.97; -16.57 minutes — p=<.0001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 VR-based Rehabilitation in the Treatment and Prevention of Sarcopenia of Older Residents
Sarcopenia
Primary: Change of Hand-grip Strength of the Dominant Hand Between the Third Month and the Baseline — 5.02 kg
Phase 2 N=16 Bioavailability of Amoxicillin Dissolved in Human Milk
Healthy
Primary: Area Under the Curve to Time Infinity (AUC to Time Infinity) — 1394.1; 1477.2 mcg*min/mL
Phase 1 N=32 Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
Non-Hodgkin's Lymphoma · Acute Leukemia in Remission · Chronic Myeloid Leukemia
Primary: Incidence of Grade II-IV Acute Graft vs. Host Disease (GVHD) — 18.8 percentage of participants
Phase 3 N=1,150 A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
Metastatic Hormone Sensitive Prostate Cancer
Primary: Radiographic Progression-Free Survival (rPFS) Based on Independent Central Review (ICR) of Bone Scan According to Prostate Cancer Clinical Trials Working Group 2 (PCWG2)…
N/A N=100 General Anesthesia With ETT vs LMA in Patients Undergoing Ablation for Atrial Fibrillation
Atrial Fibrillation
Primary: Procedure Time (Minutes) — 128.7; 137.8 minutes
Phase 3 N=36 Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
Congenital Bleeding Disorder · Haemophilia A
Primary: Haemostatic Effect During Surgery Evaluated by the Four-point Scale, Assessed by the Investigator/Surgeon at the Day of Surgery - Four-point Response Scale: Excellent…
N/A N=301 Pay-it-forward RCT for Gonorrhea and Chlamydia Testing
Gonorrhea Male · Chlamydia;M
Primary: Number of Participants Who Received the Dual Gonorrhea/Chlamydia Testing — 57; 46; 18 Participants
N/A N=31 A Prospective, Observational Study Utilizing Phasix™ Mesh During Ventral and Incisional Hernia Repair Surgery
Ventral Hernia
Primary: Number of Participants With Recurrent Ventral and Incision Hernias Post Repair With Phasix™ Mesh — 0 Participants
Phase 2 N=22 Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
Chemo Brain · Chemotherapy-related Cognitive Impairment · Chemo Fog
Primary: Change in the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) PCI Scale — 7.00; 11.55; 16.80; 16.64 units on a scale — p==0.41
N/A N=238 Multi-chip Meta-analysis of Parkinson's Disease for Clinical Validation of Small Samples of Key Genes in Disease
Parkinson's Disease
Primary: Parkinson's Key Gene — 1.502; 3.653; 0.916; 1.669 gene expression relative to GAPDH — p=<0.001
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
Phase 1 N=64 A 2-Part Single Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2006
Insomnia
Primary: Part A: Number of Participants With Treatment Emergent Adverse Events (AEs) and Treatment Emergent Serious Adverse Events (SAEs) — 7; 1; 0; 1 Participants
Phase 1 N=69 Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder
Insomnia Disorder
Primary: Mean Change From Baseline in the Average Sleep Onset Latency (SOL) From Modified-Multiple Sleep Latency Test (M-MSLT) for Each Treatment in Treatment Periods 1 to 3…
N/A N=10 The Effects of Ranolazine on Exercise Capacity in Patients With Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
Primary: Change in Exercise Capacity at 6 Weeks — 659.9; 300.5 seconds — p=0.47